|Bid||6.18 x 400|
|Ask||6.60 x 600|
|Day's Range||5.88 - 6.29|
|52 Week Range||4.10 - 15.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.80|
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives INSYS Therapeutics, Inc. a score of 66. Our analysis is based on comparing INSYS Therapeutics, Inc. with the following peers – Heron Therapeutics Inc, TESARO, Inc., BioDelivery Sciences International, Inc., Fennec Pharmaceuticals Inc., Depomed, Inc., Mylan N.V., Merck & Co., Inc., AcelRx Pharmaceuticals, Inc., GW Pharmaceuticals PLC ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for INSYS Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Categories: Yahoo FinanceINSYS Therapeutics, Inc. relative valuation is NEUTRAL and it has a fundamental analysis score of 66. Our analysis is based on comparing INSYS Therapeutics, Inc. with the following peers – Heron Therapeutics Inc, TESARO, Inc., BioDelivery Sciences International, Inc., Fennec Pharmaceuticals Inc., Depomed, Inc., Mylan N.V., Merck & Co., Inc., AcelRx Pharmaceuticals, Inc., GW Pharmaceuticals ... Read more (Read more...)
PHOENIX, Dec. 07, 2017-- INSYS Therapeutics, Inc., announced today that it has started a proof-of-concept study of two formulations of epinephrine nasal spray for the treatment of anaphylaxis, or severe ...
PHOENIX, Dec. 06, 2017-- INSYS Therapeutics, Inc., announced today that its New Drug Application for a novel formulation of buprenorphine as a sublingual spray for the management of moderate-to-severe ...
Canada is undoubtedly one of the greatest countries on earth. They’ve got universal healthcare, beautiful scenery, a whole region that speaks French and an awesome prime-minister. Now, Canada is about to reach a new milestone that would make it even better, the legalization of cannabis. Earlier this year, a bill was introduced to Canadian Parliament […]
The billionaire founder of Insys Therapeutics Inc, charged with engaging in a scheme to bribe doctors to prescribe an opioid, won the lifting of a requirement that he wear a GPS-enabled ankle monitor on Monday, which he said interfered with jogging. While federal prosecutors had argued that John Kapoor's vast wealth made him a flight risk, U.S. Magistrate Judge Jennifer Boal in Boston said she had seen no evidence that he had any intention to flee. Boal said it appeared Kapoor had for years known he was under investigation, yet never tried to flee the country.
BOSTON (AP) — The founder of a pharmaceutical company charged with leading a nationwide conspiracy to bribe doctors to prescribe an opioid pain medication has won his bid to remove his electronic monitoring bracelet.
PHOENIX, Nov. 27, 2017-- INSYS Therapeutics, Inc. announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will participate in the 29 th Annual ...
Billionaire John Kapoor “tightly controlled’’ a scheme to illegally pay doctors to help boost sales of his company’s opioid-based painkiller and attended a meeting where two physicians were offered bribes, ...
BOSTON (AP) — A pharmaceutical company founder accused of leading a conspiracy to bribe doctors to prescribe a powerful opioid pain medication will fight the charges against him and believes he will be vindicated, his attorney said Thursday.
The billionaire founder of drugmaker Insys Therapeutics Inc pleaded not guilty on Thursday to charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based spray to treat pain in cancer patients. John Kapoor, who stepped down as Insys' chief executive officer and chairman in January but remains its majority shareholder, entered his plea in Boston federal court to charges of conspiracy to commit racketeering, mail fraud and wire fraud. "He doesn't believe it's a strong case," Brian Kelly, Kapoor's lawyer, said.
Insys Therapeutics posted a bigger-than-expected quarterly loss on Thursday due to soft demand for its flagship product Subsys, an opioid cancer pain medication at the center of a federal probe of the company. Last week, John Kapoor, Insys' billionaire founder and majority shareholder, was arrested on charges that he participated in a scheme to bribe doctors to prescribe Subsys. Kapoor resigned from the company's board on Sunday.
Insys Therapeutics missed analysts’ estimates in its latest quarter and set aside roughly $150 million to cover potential settlement costs, following news that its co-founder and former CEO had been charged ...
Insys's billionaire founder John Kapoor was arrested on charges that he participated in a scheme to bribe doctors to prescribe Subsys. The company said on Sunday it recorded $150 million as its "best estimate of the minimum liability" to settle a U.S. Department of Justice investigation into Subsys.
On a per-share basis, the Chandler, Arizona-based company said it had a loss of $2.30. Losses, adjusted for non-recurring costs and stock option expense, came to 21 cents per share. The results did not ...
NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Insys Therapeutics, Inc. (NASDAQ: INSY ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 8:30 AM Eastern ...
Insys Therapeutics on Thursday reported a net loss for the third quarter, compared to a year-ago profit, amid an investigation of the U.S. drugmaker's founder on charges of bribery. The company reported a net loss of $166.3 million or $2.30 per share in the quarter ended Sept. 30, compared to a net income of $2.9 million or 4 cents per share, a year earlier. Insys recorded a $150 million charge in the latest quarter related to an ongoing federal investigation into its opioid painkiller, Subsys.